Memphis Pharmaceutical & Chemical Industries
EEGX:MPCI298.24
EGP
-4.06
(-1.34%)
Memphis Pharmaceutical & Chemical Industries
EGX:MPCI
(Egyptian Exchange)
Recent
price
298.24
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Memphis Pharmaceutical & Chemical Industries (EGX: MPCI) is an Egypt-based pharmaceutical manufacturer engaged in the research, development, formulation, production, marketing, and distribution of generic and branded human pharmaceuticals, plant-extracted active ingredients, veterinary medicines, and cosmetic preparations. The company operates through a diversified portfolio spanning multiple product categories and business activities, including human therapeutic pharmaceuticals covering cardiovascular, central nervous system, respiratory, gastrointestinal, anti-infective, musculoskeletal, dermatological, urological, and endocrine segments; diverse finished dosage forms comprising oral solids such as tablets, coated caplets, and capsules; oral liquids such as syrups and suspensions; topical treatments such as ointments, creams, and gels; sterile preparations such as injectable ampoules and ophthalmic solutions; rectal suppositories; active pharmaceutical ingredients and standardized botanical extracts, including proprietary plant-derived compounds such as Amidine, Amodin, and Khellin for dermatological and renal therapies; veterinary health products comprising oral solutions, water-soluble powders, injectables, and animal feed supplements; specialized cosmetic and dermatological skincare products; and toll manufacturing and contract packaging services for domestic and international pharmaceutical corporations. In recent strategic and operational developments, the company has undertaken comprehensive manufacturing facility upgrades in alignment with the Good Manufacturing Practice (GMP) modernization program led by its parent entity, the Holding Company for Pharmaceuticals (HoldiPharma). These capital investments include the rehabilitation and technical enhancement of sterile ampoule lines and oral solid production units to elevate compliance with international regulatory standards, expand capacity for national healthcare supply programs, and support export operations. The company has also expanded its commercial reach through strengthened export distribution agreements across regional markets and broadened contract manufacturing agreements to drive volume growth. Founded in 1940 and headquartered in Cairo, Egypt, Memphis Pharmaceutical & Chemical Industries operates as a subsidiary of the state-owned Holding Company for Pharmaceuticals and serves domestic healthcare channels while exporting to approximately 30 countries across the Middle East, Africa, and Asia.